IP Library Patent Application 12482723
Patent Application
App. No. 12/482,723

IRON METABOLISM-IMPROVING AGENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/482,723
Abstract

An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided.

Claims (19)

1 . An iron metabolism-improving agent, comprising at least one of citric acid and a citrate salt.

2 . The iron metabolism-improving agent according to claim 1 , wherein the agent comprises the at least one of citric acid and the citrate salt as an electrolyte.

3 . The iron metabolism-improving agent according to claim 1 , wherein:

the agent is free of acetic acid and acetate salts; and

the agent comprises the at least one of citric acid and the citrate salt as an electrolyte.

4 . The iron metabolism-improving agent according to claim 1 , wherein:

the agent comprises the at least one of citric acid and the citrate salt as an electrolyte;

the agent comprises at least one additional electrolyte; and

the agent comprises glucose.

5 . A dialysate, comprising the iron metabolism-improving agent according to claim 1 .

6 . A substitution fluid, comprising the iron metabolism-improving agent according to claim 1 .

7 . A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy, comprising administering the iron metabolism-improving agent according to claim 1 to the patient.

8 . The method of claim 7 , wherein the blood purification therapy is selected from the group consisting of hemodialysis, hemofiltration and hemodiafiltration.

9 . A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy, comprising administering the dialysate according to claim 5 to the patient.

10 . The method of claim 9 , wherein the blood purification therapy is selected from the group consisting of hemodialysis, hemofiltration and hemodiafiltration.

11 . A method for improving iron metabolism in a chronic renal failure patient receiving blood purification therapy, comprising administering the substitution fluid according to claim 6 to the patient.

12 . The method of claim 11 , wherein the blood purification therapy is selected from the group consisting of hemodialysis, hemofiltration and hemodiafiltration.

13 . A blood purification method, comprising performing at least one of hemodialysis and hemodiafiltration using the dialysate according to claim 5 .

14 . A blood purification method, comprising performing at least one of hemodiafiltration and hemofiltration using the substitution fluid according to claim 6 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2009
From: NAKANISHI, TAKESHI; KURAGANO, TAKAHIRO; AKAIKE, NOBUHIDE; NAKANISHI, TAKASHI
To: AJINOMOTO CO., INC.
Reel/Frame 023142/0506 →